Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The changing climate for whistleblowers

This article was originally published in SRA

Executive Summary

The $2.3 billion fine against Pfizer announced last week1 is expected to lead to far greater oversight of the way prescription drugs are marketed in the US. The record-breaking fine was a punishment for the off-label promotion of four products: the anti-inflammatory Bextra (valdecoxib), the antipsychotic Geodon (ziprasidone HCl), the antibiotic Zyvox (linezolid) and the anti-epileptic Lyrica (pregabalin).

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS114578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel